165 related articles for article (PubMed ID: 35315197)
61. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.
Lode HN; Xiang R; Pertl U; Förster E; Schoenberger SP; Gillies SD; Reisfeld RA
J Clin Invest; 2000 Jun; 105(11):1623-30. PubMed ID: 10841521
[TBL] [Abstract][Full Text] [Related]
62. Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine sarcomas.
Spugnini EP; Vincenzi B; Citro G; Santini D; Dotsinsky I; Mudrov N; Montesarchio V; Laieta MT; Esposito V; Baldi A
In Vivo; 2007; 21(5):819-22. PubMed ID: 18019417
[TBL] [Abstract][Full Text] [Related]
63. Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: A follow-up case report.
Igase M; Inanaga S; Tani K; Nakaichi M; Sakai Y; Sakurai M; Kato M; Tsukui T; Mizuno T
Vet Comp Oncol; 2022 Dec; 20(4):901-905. PubMed ID: 35535636
[TBL] [Abstract][Full Text] [Related]
64. Radiation treatment for incompletely resected soft-tissue sarcomas in dogs.
McKnight JA; Mauldin GN; McEntee MC; Meleo KA; Patnaik AK
J Am Vet Med Assoc; 2000 Jul; 217(2):205-10. PubMed ID: 10909459
[TBL] [Abstract][Full Text] [Related]
65. Prognostic significance of intratumoral microvessel density in canine soft-tissue sarcomas.
Luong RH; Baer KE; Craft DM; Ettinger SN; Scase TJ; Bergman PJ
Vet Pathol; 2006 Sep; 43(5):622-31. PubMed ID: 16966439
[TBL] [Abstract][Full Text] [Related]
66. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
67. Outcome following removal of canine spindle cell tumours in first opinion practice: 104 cases.
Chase D; Bray J; Ide A; Polton G
J Small Anim Pract; 2009 Nov; 50(11):568-74. PubMed ID: 19814769
[TBL] [Abstract][Full Text] [Related]
68. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
[TBL] [Abstract][Full Text] [Related]
69. Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.
Uher O; Hadrava Vanova K; Lencova R; Frejlachova A; Wang H; Zhuang Z; Zenka J; Pacak K
Front Endocrinol (Lausanne); 2023; 14():1030412. PubMed ID: 37342258
[TBL] [Abstract][Full Text] [Related]
70. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T
Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170
[TBL] [Abstract][Full Text] [Related]
71. Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma.
Flesner BK; Wood GW; Gayheart-Walsten P; Sonderegger FL; Henry CJ; Tate DJ; Bechtel SM; Donnelly LL; Johnson GC; Kim DY; Wahaus TA; Bryan JN; Reyes N
J Vet Intern Med; 2020 Sep; 34(5):2056-2067. PubMed ID: 32649801
[TBL] [Abstract][Full Text] [Related]
72. The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study.
Haagsman AN; Witkamp AC; Sjollema BE; Kik MJ; Kirpensteijn J
BMC Vet Res; 2013 Aug; 9():155. PubMed ID: 23927575
[TBL] [Abstract][Full Text] [Related]
73. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
Lau SP; van 't Land FR; van der Burg SH; Homs MYV; Lolkema MP; Aerts JGJV; van Eijck CHJ
BMJ Open; 2022 Jun; 12(6):e060431. PubMed ID: 35710239
[TBL] [Abstract][Full Text] [Related]
74. Radiation plus local hyperthermia versus radiation plus the combination of local and whole-body hyperthermia in canine sarcomas.
Thrall DE; Prescott DM; Samulski TV; Rosner GL; Denman DL; Legorreta RL; Dodge RK; Page RL; Cline JM; Lee J; Case BC; Evans SM; Oleson JR; Dewhirst MW
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1087-96. PubMed ID: 8600092
[TBL] [Abstract][Full Text] [Related]
75. Diagnostic accuracy of pre-treatment biopsy for grading soft tissue sarcomas in dogs.
Perry JA; Culp WT; Dailey DD; Eickhoff JC; Kamstock DA; Thamm DH
Vet Comp Oncol; 2014 Jun; 12(2):106-13. PubMed ID: 22617002
[TBL] [Abstract][Full Text] [Related]
76. Doxorubicin is a widely used chemotherapeutic agent with activity reported in many malignancies, including soft tissue sarcomas.
Greenberg MH; Friedland ML
Cancer Invest; 1989; 7(5):523. PubMed ID: 2620253
[No Abstract] [Full Text] [Related]
77. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
78. Endobronchial metastasis in a dog with sarcoma.
Schaffer PA; Weishaar KM; Han S
J Vet Diagn Invest; 2013 Jul; 25(4):546-50. PubMed ID: 23782718
[TBL] [Abstract][Full Text] [Related]
79. Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas.
Thrall DE; Larue SM; Pruitt AF; Case B; Dewhirst MW
Int J Hyperthermia; 2006 Aug; 22(5):365-73. PubMed ID: 16891239
[TBL] [Abstract][Full Text] [Related]
80. The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia.
Pazzi P; Celliers A; du Plessis EC; Kristensen AT; Goddard A
Vet Comp Oncol; 2022 Mar; 20(1):154-163. PubMed ID: 34314552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
